Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 39: 2466-2469, 1993;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engler, H.
Right arrow Articles by Riesen, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engler, H.
Right arrow Articles by Riesen, W. F.

Clinical Chemistry, Vol 39, 2466-2469, Copyright © 1993 by American Association for Clinical Chemistry

Effect of thyroid function on concentrations of lipoprotein(a)

H Engler and WF Riesen
Institute of Clinical Chemistry and Hematology, State Hospital, St. Gallen, Switzerland.

The effect of thyroid hormones on concentrations of lipoprotein(a) [Lp(a)] was analyzed in 60 patients with active thyroid dysfunction (hyperthyroidism 30 cases, hypothyroidism 32 cases, and 2 cases with opposite changes) and after normalization of the thyroid state. Treatment of hyperthyroidism increased the mean Lp(a) concentrations by 60% (from 73 to 102 mg/L, P < 0.002); at the same time, low-density lipoprotein cholesterol (LDL-C) increased by 53% (from 2.6 to 3.7 mmol/L, P < 0.0001) and apolipoprotein B (apo B) by 35% (from 0.91 to 1.17 g/L, P < 0.0005). In hypothyroidism, the opposite changes were observed: mean Lp(a) decreased from 136 to 114 mg/L (10%, P < 0.02), LDL-C from 4.6 to 3.9 mmol/L (13%, P < 0.01), and apo B from 1.51 to 1.20 g/L (14%, P < 0.01). Although the changes in Lp(a) concentrations did correlate with changes of LDL-C during treatment of hyperthyroidism (r = 0.43, P < 0.05), and with changes in apo B during thyroxine- substitution therapy for hypothyroidism (r = 0.46, P < 0.05), we observed no associations between Lp(a) and LDL-C or apo B in the euthyroid state. These data cannot rule out the possibility that the thyroid hormone-induced increase in LDL-C receptor activity was responsible for the decreased concentrations of Lp(a) in hyperthyroidism. Given that LDL-C is approximately 30% of the Lp(a) molecule but the changes in Lp(a) concentrations are comparable with those in LDL-C (60% vs 53%), and given that Lp(a) is metabolized by an LDL-C-receptor-independent pathway, the present data suggest a direct effect of thyroid hormones on Lp(a) synthesis.


The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
X. Guang-da, S. Hui-ling, C. Zhi-song, and Z. Lin-shuang
Changes in Plasma Concentrations of Osteoprotegerin before and after Levothyroxine Replacement Therapy in Hypothyroid Patients
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5765 - 5768.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. J. Grover, D. M. Egan, P. G. Sleph, B. C. Beehler, G. Chiellini, N.-H. Nguyen, J. D. Baxter, and T. S. Scanlan
Effects of the Thyroid Hormone Receptor Agonist GC-1 on Metabolic Rate and Cholesterol in Rats and Primates: Selective Actions Relative to 3,5,3'-Triiodo-L-Thyronine
Endocrinology, April 1, 2004; 145(4): 1656 - 1661.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
E. S. Ganotakis, K. Mandalaki, M. Tampakaki, N. Malliaraki, E. Mandalakis, G. Vrentzos, J. Melissas, and E. Castanas
Subclinical Hypothyroidism and Lipid Abnormalities in Older Women Attending a Vascular Disease Prevention Clinic: Effect of Thyroid Replacement Therapy
Angiology, September 1, 2003; 54(5): 569 - 576.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. J. Grover, K. Mellstrom, L. Ye, J. Malm, Y.-L. Li, L.-G. Bladh, P. G. Sleph, M. A. Smith, R. George, B. Vennstrom, et al.
Selective thyroid hormone receptor-{beta} activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability
PNAS, August 19, 2003; 100(17): 10067 - 10072.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Caraccio, E. Ferrannini, and F. Monzani
Lipoprotein Profile in Subclinical Hypothyroidism: Response to Levothyroxine Replacement, a Randomized Placebo-Controlled Study
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1533 - 1538.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Korte, J. Greiner, A. Feldges, and W. F. Riesen
Increased Lipoprotein(a) levels are not a steady prothrombotic defect
Blood, September 15, 2001; 98(6): 1993 - 1994.
[Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
H. J Milionis, A. F Winder, and D. P Mikhailidis
Lipoprotein (a) and stroke
J. Clin. Pathol., July 1, 2000; 53(7): 487 - 496.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. von Eckardstein, S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann, and H. M. Behre
Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a)
J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3367 - 3372.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
G. Jurgens, W. C. Taddei-Peters, P. Koltringer, W. Petek, Q. Chen, J. Greilberger, P. F. Macomber, B. T. Butman, A. G. Stead, and J. H. Ransom
Lipoprotein(a) Serum Concentration and Apolipoprotein(a) Phenotype Correlate With Severity and Presence of Ischemic Cerebrovascular Disease
Stroke, October 1, 1995; 26(10): 1841 - 1848.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Association for Clinical Chemistry.